Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Mark_A._Goldsmith
|
| gptkbp:collaboratesWith |
gptkb:Sanofi
|
| gptkbp:developedBy |
targeted cancer therapies
RAS(ON) Inhibitors |
| gptkbp:focusesOn |
oncology
cancer therapeutics |
| gptkbp:foundedIn |
2014
|
| gptkbp:founder |
gptkb:Mark_A._Goldsmith
|
| gptkbp:headquartersLocation |
gptkb:Redwood_City,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Revolution Medicines
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:listedOn |
gptkb:NASDAQ
|
| gptkbp:notableProduct |
gptkb:RMC-4630
gptkb:RMC-5552 RMC-6236 |
| gptkbp:numberOfEmployees |
over 200
|
| gptkbp:publiclyTraded |
yes
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:RVMD
|
| gptkbp:website |
https://www.revmed.com/
|
| gptkbp:bfsParent |
gptkb:Warp_Drive_Bio
|
| gptkbp:bfsLayer |
5
|